RT Journal Article
T1 Targeting Protein Kinases to Enhance the Response to anti-PD-1/PD-L1 Immunotherapy.
A1 García-Aranda, Marilina
A1 Redondo, Maximino
K1 MHC
K1 cancer
K1 checkpoint blockade
K1 immunotherapy
K1 inhibitor
K1 kinase
K1 resistance
K1 tumor escape
AB The interaction between programmed cell death protein (PD-1) and its ligand (PD-L1) is one of the main pathways used by some tumors to escape the immune response. In recent years, immunotherapies based on the use of antibodies against PD-1/PD-L1 have been postulated as a great promise for cancer treatment, increasing total survival compared to standard therapy in different tumors. Despite the hopefulness of these results, a significant percentage of patients do not respond to such therapy or will end up evolving toward a progressive disease. Besides their role in PD-L1 expression, altered protein kinases in tumor cells can limit the effectiveness of PD-1/PD-L1 blocking therapies at different levels. In this review, we describe the role of kinases that appear most frequently altered in tumor cells and that can be an impediment for the success of immunotherapies as well as the potential utility of protein kinase inhibitors to enhance the response to such treatments.
YR 2019
FD 2019-05-09
LK http://hdl.handle.net/10668/13941
UL http://hdl.handle.net/10668/13941
LA en
DS RISalud
RD Apr 8, 2025